Support for EPIC Act - S. 839, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model.
2025 · 3rd Quarter (July 1 - Sep 30)
GILEAD SCIENCES, INC.
Filed by THE MCMANUS GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2025
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- THE MCMANUS GROUP
- Client
- GILEAD SCIENCES, INC.
- Filing UUID
- 583bd95e-2948-4423-aa1b-94763f5a21e3
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to federal funding for HIV prevention.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.